377 related articles for article (PubMed ID: 30275007)
1. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
Wei Y; Zheng H; Bao N; Jiang S; Bueso-Ramos CE; Khoury J; Class C; Lu Y; Lin K; Yang H; Ganan-Gomez I; Starczynowski DT; Do KA; Colla S; Garcia-Manero G
Blood Adv; 2018 Oct; 2(19):2491-2504. PubMed ID: 30275007
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y; Kanagal-Shamanna R; Zheng H; Bao N; Lockyer PP; Class CA; Darbaniyan F; Lu Y; Lin K; Yang H; Montalban-Bravo G; Ganan-Gomez I; Soltysiak KA; Do KA; Colla S; Garcia-Manero G
Leukemia; 2022 Aug; 36(8):2097-2107. PubMed ID: 35697791
[TBL] [Abstract][Full Text] [Related]
3. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
Wei Y; Chen R; Dimicoli S; Bueso-Ramos C; Neuberg D; Pierce S; Wang H; Yang H; Jia Y; Zheng H; Fang Z; Nguyen M; Ganan-Gomez I; Ebert B; Levine R; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Nov; 27(11):2177-86. PubMed ID: 23538751
[TBL] [Abstract][Full Text] [Related]
4. Deconstructing innate immune signaling in myelodysplastic syndromes.
Varney ME; Melgar K; Niederkorn M; Smith M; Barreyro L; Starczynowski DT
Exp Hematol; 2015 Aug; 43(8):587-598. PubMed ID: 26143580
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
6. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.
Cheng P; Eksioglu EA; Chen X; Kandell W; Le Trinh T; Cen L; Qi J; Sallman DA; Zhang Y; Tu N; Adams WA; Zhang C; Liu J; Cleveland JL; List AF; Wei S
Leukemia; 2019 Aug; 33(8):2034-2046. PubMed ID: 30737486
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor alterations in myelodysplastic syndrome.
Wei Y; Dimicoli S; Bueso-Ramos C; Chen R; Yang H; Neuberg D; Pierce S; Jia Y; Zheng H; Wang H; Wang X; Nguyen M; Wang SA; Ebert B; Bejar R; Levine R; Abdel-Wahab O; Kleppe M; Ganan-Gomez I; Kantarjian H; Garcia-Manero G
Leukemia; 2013 Sep; 27(9):1832-40. PubMed ID: 23765228
[TBL] [Abstract][Full Text] [Related]
8. Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation.
Cui P; Zhang Y; Cui M; Li Z; Ma G; Wang R; Wang N; Huang S; Gao J
Leuk Res; 2018 Feb; 65():49-54. PubMed ID: 29306107
[TBL] [Abstract][Full Text] [Related]
9. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
Varney ME; Niederkorn M; Konno H; Matsumura T; Gohda J; Yoshida N; Akiyama T; Christie S; Fang J; Miller D; Jerez A; Karsan A; Maciejewski JP; Meetei RA; Inoue J; Starczynowski DT
J Exp Med; 2015 Oct; 212(11):1967-85. PubMed ID: 26458771
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.
Fang J; Bolanos LC; Choi K; Liu X; Christie S; Akunuru S; Kumar R; Wang D; Chen X; Greis KD; Stoilov P; Filippi MD; Maciejewski JP; Garcia-Manero G; Weirauch MT; Salomonis N; Geiger H; Zheng Y; Starczynowski DT
Nat Immunol; 2017 Feb; 18(2):236-245. PubMed ID: 28024152
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF subunit expression heterogeneity in human aplastic anemia stem/progenitors.
Sinha S; Chatterjee SS; Biswas M; Nag A; Banerjee D; De R; Sengupta A
Exp Hematol; 2018 Jun; 62():39-44.e2. PubMed ID: 29596882
[TBL] [Abstract][Full Text] [Related]
12. JMJD3 aids in reprogramming of bone marrow progenitor cells to hepatic phenotype through epigenetic activation of hepatic transcription factors.
Kochat V; Equbal Z; Baligar P; Kumar V; Srivastava M; Mukhopadhyay A
PLoS One; 2017; 12(3):e0173977. PubMed ID: 28328977
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome.
Pribadi C; Camp E; Cakouros D; Anderson P; Glackin C; Gronthos S
Stem Cell Res Ther; 2020 Dec; 11(1):529. PubMed ID: 33298158
[TBL] [Abstract][Full Text] [Related]
14. Reduced Erg Dosage Impairs Survival of Hematopoietic Stem and Progenitor Cells.
Xie Y; Koch ML; Zhang X; Hamblen MJ; Godinho FJ; Fujiwara Y; Xie H; Klusmann JH; Orkin SH; Li Z
Stem Cells; 2017 Jul; 35(7):1773-1785. PubMed ID: 28436588
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
[TBL] [Abstract][Full Text] [Related]
16. Histone demethylase KDM6B regulates human podocyte differentiation
Guo Y; Xiong Z; Guo X
Biochem J; 2019 Jun; 476(12):1741-1751. PubMed ID: 31138771
[TBL] [Abstract][Full Text] [Related]
17. Alcohol-induced suppression of KDM6B dysregulates the mineralization potential in dental pulp stem cells.
Hoang M; Kim JJ; Kim Y; Tong E; Trammell B; Liu Y; Shi S; Lee CR; Hong C; Wang CY; Kim Y
Stem Cell Res; 2016 Jul; 17(1):111-21. PubMed ID: 27286573
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated hematopoiesis caused by mammary cancer is associated with epigenetic changes and hox gene expression in hematopoietic cells.
Sio A; Chehal MK; Tsai K; Fan X; Roberts ME; Nelson BH; Grembecka J; Cierpicki T; Krebs DL; Harder KW
Cancer Res; 2013 Oct; 73(19):5892-904. PubMed ID: 23913828
[TBL] [Abstract][Full Text] [Related]
19. TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
Monlish DA; Greenberg ZJ; Bhatt ST; Leonard KM; Romine MP; Dong Q; Bendesky L; Duncavage EJ; Magee JA; Schuettpelz LG
Exp Hematol; 2020 Aug; 88():42-55. PubMed ID: 32652111
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
